Entellus Medical Inc. (NASDAQ:ENTL) saw strong trading volume on Monday . 54,617 shares traded hands during trading, a decline of 24% from the previous session’s volume of 71,469 shares.The stock last traded at $18.27 and had previously closed at $18.20.

A number of equities analysts have recently issued reports on ENTL shares. Bank of America Corp. reissued a “buy” rating on shares of Entellus Medical in a research note on Monday. Zacks Investment Research downgraded Entellus Medical from a “hold” rating to a “sell” rating in a research note on Thursday, April 14th. BTIG Research started coverage on Entellus Medical in a research note on Tuesday, June 14th. They set a “buy” rating and a $22.00 target price for the company. Finally, Canaccord Genuity reissued a “buy” rating and set a $23.00 target price on shares of Entellus Medical in a research note on Wednesday, June 29th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $23.80.

The stock has a 50-day moving average price of $18.16 and a 200 day moving average price of $16.85. The firm’s market capitalization is $338.72 million.

Entellus Medical (NASDAQ:ENTL) last announced its earnings results on Wednesday, May 4th. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.10. During the same period in the previous year, the firm posted ($0.35) earnings per share. The business had revenue of $16.90 million for the quarter, compared to analysts’ expectations of $16.34 million. The firm’s revenue was up 25.2% compared to the same quarter last year. On average, analysts anticipate that Entellus Medical Inc. will post ($1.32) earnings per share for the current year.

In other news, VP Timothy B. Petrick sold 3,000 shares of Entellus Medical stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $18.15, for a total transaction of $54,450.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

A hedge fund recently raised its stake in Entellus Medical stock. Wells Fargo & Company MN raised its position in Entellus Medical Inc. (NASDAQ:ENTL) by 7.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 464,550 shares of the medical technology company’s stock after buying an additional 31,082 shares during the period. Wells Fargo & Company MN owned about 2.47% of Entellus Medical worth $7,832,000 at the end of the most recent reporting period.

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.